Abstract
Pemetrexed is a multi-targeted folate antagonist drug approved for the treatment of advanced and metastatic non-small cell lung carcinoma (NSCLC), and malignant pleural mesothelioma, and is known to induce cutaneous adverse reactions in approximately 20% of patients. We report a case of an uncommon toxicity induced by pemetrexed: scleroderma-like condition of the lower extremities. This cutaneous adverse effect is often unrecognized, resulting in delayed diagnosis, which often leads to a worsening in the condition and increasing the risk of further fibrosing sequelae.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
